Ipsogen gets microarray license:
This article was originally published in Clinica
French molecular diagnostics specialist Ipsogen has gained non-exclusive worldwide rights to Affymetrix's microarray technology to incorporate into its in vitro diagnostic (IVD) tests. Ipsogen (headquartered in Marseille) will develop IVDs initially for breast cancer. Financial details of the deal were not disclosed.